Abstract
We report our experience of providing chronic opioid pharmacotherapy on an outpatient basis to selected patients with frequent episodes of moderate-to-severe pain from sickle cell disease (SCD). Three cases illustrate our clinical experience in approximately 40 patients with sickle cell pain. Patients were seen at our sickle cell pain clinic at Beth Israel Hospital once each month for a three-hour visit. Visits included group music therapy and individual medical care, including comprehensive blood work and scheduling of medical tests when appropriate. Between visits, the pain and palliative care physicians followed patients on an as-needed basis. The SCD pain opioid pharmacotherapy protocol was modeled on a regimen used to treat malignant pain-typically a long-acting opioid in combination with a short-acting opioid, such as oral transmucosal fentanyl citrate (OTFC; Actiq) for breakthrough pain (BTP). Emergency department (ED) visits and hospital admissions were dramatically reduced in the three patients whose pain was managed by adapting the cancer pain model. During the year before their first visit to our pain clinic, the patients each had between six and 18 ED visits, which resulted in six- to 13 hospital admissions amounting to 32-182 inpatient days per patient. Each of the patients was prescribed a long-acting opioid (methadone, control-release oxycodone, or transdermal fentanyl) with a short-acting opioid for BTP from crises (oral transmucosal fentanyl citrate for two patients; short-acting oxycodone for one patient). Pain was well controlled. For each patient, hospital admissions were reduced to < or = 1 visit per year. These reduced levels of ED visits and hospital admissions have remained constant for more than three years.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benjamin L. J., Swinson G. I., Nagel R. L. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000 Feb 15;95(4):1130–1136. [PubMed] [Google Scholar]
- Brookoff D., Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med. 1992 Mar 1;116(5):364–368. doi: 10.7326/0003-4819-116-5-364. [DOI] [PubMed] [Google Scholar]
- Christie J. M., Simmonds M., Patt R., Coluzzi P., Busch M. A., Nordbrock E., Portenoy R. K. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998 Oct;16(10):3238–3245. doi: 10.1200/JCO.1998.16.10.3238. [DOI] [PubMed] [Google Scholar]
- Coluzzi P. H., Schwartzberg L., Conroy J. D., Charapata S., Gay M., Busch M. A., Chavez J., Ashley J., Lebo D., McCracken M. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001 Mar;91(1-2):123–130. doi: 10.1016/s0304-3959(00)00427-9. [DOI] [PubMed] [Google Scholar]
- Lichtor J. L., Sevarino F. B., Joshi G. P., Busch M. A., Nordbrock E., Ginsberg B. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg. 1999 Sep;89(3):732–738. doi: 10.1097/00000539-199909000-00038. [DOI] [PubMed] [Google Scholar]
- Martin J. J., Moore G. P. Pearls, pitfalls, and updates for pain management. Emerg Med Clin North Am. 1997 May;15(2):399–415. doi: 10.1016/s0733-8627(05)70307-2. [DOI] [PubMed] [Google Scholar]
- Pack-Mabien A., Labbe E., Herbert D., Haynes J., Jr Nurses' attitudes and practices in sickle cell pain management. Appl Nurs Res. 2001 Nov;14(4):187–192. doi: 10.1053/apnr.2001.26783. [DOI] [PubMed] [Google Scholar]
- Portenoy R. K., Hagen N. A. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990 Jun;41(3):273–281. doi: 10.1016/0304-3959(90)90004-W. [DOI] [PubMed] [Google Scholar]
- Portenoy R. K., Payne R., Coluzzi P., Raschko J. W., Lyss A., Busch M. A., Frigerio V., Ingham J., Loseth D. B., Nordbrock E. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999 Feb;79(2-3):303–312. doi: 10.1016/s0304-3959(98)00179-1. [DOI] [PubMed] [Google Scholar]
- Shapiro B. S., Benjamin L. J., Payne R., Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997 Sep;14(3):168–174. doi: 10.1016/S0885-3924(97)00019-5. [DOI] [PubMed] [Google Scholar]